Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab

Lignende værker

• Baseline Serum Albumin Is a Predictive Biomarker for Patients With Advanced Pancreatic Cancer Treated With Bevacizumab: A Pooled Analysis of 7 Prospective Trials of Gemcitabine-Based Therapy With or Without Bevacizumab
  af: Pant, Shubham, et al.
  Udgivet: (2014)
• Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer?: A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab
  af: Van Loon, Katherine, et al.
  Udgivet: (2014)
• VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA
  af: Martin, L. K., et al.
  Udgivet: (2012)
• FOLFIRINOX in Locally Advanced Pancreas Adenocarcinoma: Back to the Future?
  af: Bekaii-Saab, Tanios, et al.
  Udgivet: (2013)
• Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer
  af: Martin, Ludmila Katherine, et al.
  Udgivet: (2012)